Adverse reactions during infliximab infusion in children and adolescents - Multicenter study;Efeitos adversos durante a infusão de infliximabe em crianças e adolescentes - Estudo multicêntrico

Revista Brasileira de Reumatologia

Volumn 48, Issue 5, 2008, Pages 278-282

  Barbosa, Cássia Maria Passarelli Lupoli ^a,e   Terreri, Maria Teresa R A ^a   Oliveira, Sheila K F ^b   Rodrigues, Marta Cristine Felix ^b   Bica, Blanca Elena Rios Gomes ^b   Sacchetti, Silvana ^c   Romanelli, Paulo Roberto Stocco ^d   Len, Cláudio Arnaldo ^a   Hilário, Maria Odete Esteves ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Servico de Infectologia Pediatrica   (Brazil)

^d SMS

^e PMSP ^*  (Brazil)

Author keywords

Adverse reactions; Anti TNF; Children; Infliximab; Infusion reactions

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB;

ADOLESCENT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOSIS; DATA ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMERGENCY CARE; FLUSHING; FOLLOW UP; HUMAN; HYPERTENSION; HYPOTENSION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; ONSET AGE; PEDIATRICS; REFRACTORY PERIOD; RETROSPECTIVE STUDY; RHEUMATOLOGY; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT INDICATION; URTICARIA;

EID: 58149181431     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Culy CR, Keating GM: Etanercept, an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62: 2493-537, 2002.
2. Asadullah K, Docke WD, Volk HD, Sterry W: The pathophysiological role of cytokines in psoriasis. Drugs Today 12: 923-4, 1999.
3. Ardizzone S, Porro GB: Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 252: 475-96, 2002.
4. Hashkes PJ, Laxer RM: Medical treatment of Juvenile Idiopathic Arthritis. JAMA 29: 1671-84, 2005.
5. Lovell DJ, Giannini EH, Reiff A, et al.: Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48: 218-26, 2003.
6. Lahdenne P, Vahasalo P, Honkanen V: Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62: 245-7, 2003.
7. Gerloni V, Pontikaki I, Gattinara M, et al.: Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis. Arthritis Rheum 52: 548-53, 2005.
8. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al.: Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: result of a multinational survey. J Rheumatol 34: 1146-50, 2007.
9. Crandall WV, Mackner LM: Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17:75-84, 2003.
10. Kolho K-L, Ruuska T, Savilahti E: Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatrica 96: 128-34, 2007.
11. de Oliveira SK, de Almeida RG, Fonseca AR, et al.: Indications and adverse events with the use of anti-TNF alpha agents in pediatric rheumatology experience of a single center. Acta Rheumatol Port 32: 139-50, 2007.
12. Pontikaki I, Gerloni V, Gattinara M, et al.: Effetti collaterali del trattamento com inibitori del TNFα nell'artrite idiopatica giovanile. Reumatismo 58: 31-8, 2006.
13. Jacobstein DA, Markowitz JE, Kirschner BS, et al.: Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11: 442-6, 2005.
14. Miele E, Markowitz JE, Mamula P, Baldassano RN: Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38: 502-8, 2004.
15. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-8, 2003.
16. Ruperto N, Lovell DJ, Cuttica R, et al.: A randomized, placebo-controled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56: 3096-106, 2007.